A New Strategy for Chronic Endometritis Treatment Using Fermented Soy Product (ImmuBalance^™)

Area of Science:

• Reproductive Medicine
• Microbiome Research
• Gynecological Pathology

Background:

• Chronic endometritis (CE) is a significant factor in repeated implantation failure (RIF).
• Standard antibiotic treatments for CE do not always lead to resolution.
• Alternative therapies are needed for persistent CE cases.

Purpose of the Study:

• To investigate the efficacy of ImmuBalance (IMB), a pre- and probiotic combination, as an alternative treatment for chronic endometritis (CE).
• To evaluate IMB's effectiveness in patients with CE unresponsive to conventional antibiotic therapy.

Main Methods:

• A retrospective study analyzed 819 women with CE between April 2021 and August 2022.
• Patients received initial treatment with doxycycline or IMB.
• Subsequent treatments included different antibiotic regimens or IMB for non-responsive cases, with CD138+ plasma cell counts assessed.

Main Results:

• ImmuBalance (IMB) treatment resulted in significant reduction of CD138+ plasma cells in Groups 2 and 3 (p<0.01 and p=0.04, respectively).
• CE resolution was achieved in 100% of patients treated with IMB in Groups 2 and 3 (15/15 and 4/4).
• Initial IMB use in Group 1 showed a 60% resolution rate, though not statistically significant (p=0.13).

Conclusions:

• ImmuBalance (IMB) demonstrates potential as an effective treatment for chronic endometritis (CE).
• IMB may be particularly beneficial for patients who have not responded to antibiotic treatments.
• This study suggests IMB as a viable option for managing CE, potentially improving outcomes in RIF.